IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD

被引:14
作者
Han, Chenying [1 ]
Hu, Chenchen [1 ]
Liu, Tianyue [1 ]
Sun, Yuanjie [1 ]
Hu, Feiming [1 ]
He, Yuanli [1 ]
Zhang, Jiaxing [1 ]
Chen, Jiaxi [1 ,2 ]
Ding, Jiaqi [1 ,3 ]
Fan, Jiangjiang [1 ,4 ]
Zhang, Xiyang [5 ]
Wang, Jing [1 ]
Qiao, Xupeng [1 ]
Jiang, Dongbo [1 ]
Yang, Kun [1 ,6 ]
Yang, Shuya [1 ]
机构
[1] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian 710032, Shaanxi, Peoples R China
[3] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian 710038, Peoples R China
[5] Fourth Mil Med Univ, Mil Med Innovat Ctr, Xian 710032, Shaanxi, Peoples R China
[6] Air Force Med Univ, Tangdu Hosp, Dept Rheumatol & Immunol, Xian 710038, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
RNA-BINDING PROTEINS; METASTASIS; DEPLETION;
D O I
10.1038/s41419-024-06520-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cervical cancer (CC) is the most common gynecologic malignancy, which seriously threatens the health of women. Lipid metabolism is necessary for tumor proliferation and metastasis. However, the molecular mechanism of the relationship between CC and lipid metabolism remains poorly defined. We revealed the expression of IGF2BP3 in CC exceeded adjacent tissues, and was positively associated with tumor stage using human CC tissue microarrays. The Cell Counting Kit-8, colony formation assay, 5-ethynyl-2 '-deoxyuridine assay, transwell assays, wound-healing assays, and flow cytometry assessed the role of IGF2BP3 in proliferation and metastasis of CC cells. Besides, exploring the molecular mechanism participating in IGF2BP3-driven lipid metabolism used RNA-seq, which determined SCD as the target of IGF2BP3. Further, lipid droplets, cellular triglyceride (TG) contents, and fatty acids were accessed to discover that IGF2BP3 can enhance lipid metabolism in CC. Moreover, RIP assay and methylated RNA immunoprecipitation experiments seeked the aimed-gene-binding specificity. Lastly, the IGF2BP3 knockdown restrained CC growth and lipid metabolism, after which SCD overexpression rescued the influence in vitro and in vivo using nude mouse tumor-bearing model. Mechanistically, IGF2BP3 regulated SCD mRNA m6A modifications via IGF2BP3-METTL14 complex, thereby enhanced CC proliferation, metastasis, and lipid metabolism. Our study highlights IGF2BP3 plays a crucial role in CC progression and represents a therapeutic latent strategy. It is a potential tactic that blocks the metabolic pathway relevant to IGF2BP3 with the purpose of treating CC.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer
    Schott, Annekatrin
    Simon, Theresa
    Muller, Simon
    Rausch, Alexander
    Busch, Bianca
    Glass, Markus
    Misiak, Danny
    Dipto, Mohammad
    Elrewany, Hend
    Peters, Lara Meret
    Tripathee, Sunita
    Ghazy, Ehab
    Mueller, Florian
    Rolnik, Robin Benedikt
    Lederer, Marcell
    Hmedat, Ali
    Vetter, Martina
    Wallwiener, Markus
    Sippl, Wolfgang
    Huettelmaier, Stefan
    Bley, Nadine
    NAR CANCER, 2025, 7 (01):
  • [42] lncRNA MIR4435-2HG promotes the progression of liver cancer by upregulating B3GNT5 expression
    Zhu, Yungang
    Li, Baoguo
    Xu, Guoping
    Han, Changrui
    Xing, Gang
    MOLECULAR MEDICINE REPORTS, 2022, 25 (01)
  • [43] Hsa_circ_0001756 promotes ovarian cancer progression through regulating IGF2BP2-mediated RAB5A expression and the EGFR/MAPK signaling pathway
    Ji, Jing
    Li, Chen
    Wang, Jinfeng
    Wang, Lei
    Huang, Huifang
    Li, Ying
    Fang, Jing
    CELL CYCLE, 2022, 21 (07) : 685 - 696
  • [44] m6A-modified exosome-derived circHIF1α binding to KH domain of IGF2BP3 mediates DNA damage and arrests G1/S transition phase to resists bacterial infection in bacteremia
    Yu, Jiang
    Gao, Yidan
    Liu, Fei
    Zhang, Yuyu
    Li, Jianda
    Ding, Luogang
    Ren, Sufang
    Yang, Jie
    Jiao, Jian
    Feng, Gong
    Chen, Zhi
    Sun, Wenbo
    Wu, Jiaqiang
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [45] SH3BP1-induced Rac-Wave2 pathway activation regulates cervical cancer cell migration, invasion, and chemoresistance to cisplatin
    Wang, Jingjing
    Feng, Yeqian
    Chen, Xishan
    Du, Zheng
    Jiang, Shaijun
    Ma, Shuyun
    Zou, Wen
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (02) : 1733 - 1745
  • [46] Catalpol Suppresses Proliferation and Facilitates Apoptosis of OVCAR-3 Ovarian Cancer Cells through Upregulating MicroRNA-200 and Downregulating MMP-2 Expression
    Gao, Na
    Tian, Jian-Xin
    Shang, Yu-Hong
    Zhao, Dan-Yi
    Wu, Tao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (11): : 19394 - 19405
  • [47] ymiR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer
    Jin, Shanshan
    Wang, Wenting
    Xu, Xinrui
    Yu, Zhaowei
    Feng, Zihan
    Xie, Jun
    Lv, Huimin
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (05): : 740 - 752
  • [48] METTL3/IGF2BP1 promotes the development of triple-negative breast cancer by mediating m6A methylation modification of PRMT7
    Lu, Wanli
    Yang, Shenghu
    TISSUE & CELL, 2025, 93
  • [49] Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1
    Huang, Wenjing
    Yan, Yanyan
    Liu, Yun
    Lin, Minting
    Ma, Jinxiang
    Zhang, Wei
    Dai, Jianwei
    Li, Jiajun
    Guo, Qiaoru
    Chen, Hubiao
    Makabel, Bolat
    Liu, Hong
    Su, Chaoyue
    Bi, Hong
    Zhang, Jianye
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [50] EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling
    Jiang, Xingkang
    Guo, Shanqi
    Wang, Shuo
    Zhang, Yangyi
    Chen, Haojie
    Wang, Yong
    Liu, Ranlu
    Niu, Yuanjie
    Xu, Yong
    CANCER RESEARCH, 2022, 82 (05) : 831 - 845